GCP
KLRS

GSA Capital Partners’s Kalaris Therapeutics KLRS Stock Holding History

GSA Capital Partners’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,227
Closed -$37K – 2089
2024
Q2 		$37K Sell
2,227
-7,626
-77% -$135K ﹤0.01% 1572
2024
Q1 		$171K Buy
9,853
+776
+9% +$12.7K 0.01% 1432
2023
Q4 		$142K Buy
+9,077
New +$358K 0.01% 1372
2023
Q3 		– Sell
-955
Closed -$75K – 1988
2023
Q2 		$75K Sell
955
-1,088
-53% -$103K 0.01% 1399
2023
Q1 		$185K Sell
2,043
-957
-32% -$122K 0.02% 1271
2022
Q4 		$354K Sell
3,000
-375
-11% -$63.6K 0.04% 820
2022
Q3 		$612K Buy
3,375
+982
+41% +$153K 0.08% 424
2022
Q2 		$215K Sell
2,393
-1,658
-41% -$174K 0.03% 1038
2022
Q1 		$629K Sell
4,051
-715
-15% -$143K 0.08% 394
2021
Q4 		$1.42M Buy
+4,766
New +$2.21M 0.18% 88

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

GSA Capital Partners's KLRS Position: Q3 2024 in Review

GSA Capital Partners sold out of Kalaris Therapeutics (KLRS) in Q3 2024, closing a stake of 2,227 shares — an estimated $37K sold.

GSA Capital Partners first reported a position in KLRS in Q4 2021 and held it in 10 quarters. The position peaked at $1.42M in Q4 2021. 59 funds tracked by Wall St. Rank hold KLRS as of Q3 2024.

  • GSA Capital Partners reported no remaining Kalaris Therapeutics position as of Q3 2024 after selling out during the quarter.
  • GSA Capital Partners sold 2,227 Kalaris Therapeutics shares in Q3 2024, an estimated $37K.
  • GSA Capital Partners first reported a position in Kalaris Therapeutics in Q4 2021 and held it in 10 quarters.
  • GSA Capital Partners's Kalaris Therapeutics position peaked at $1.42M in Q4 2021.
  • 59 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2024.

Based on GSA Capital Partners's 13F filing for Q3 2024, filed 5 Nov 2024.